Shares of Oncolytics Biotech Inc. (TSE:ONC - Get Free Report) were up 24.1% during trading on Tuesday . The stock traded as high as C$1.72 and last traded at C$1.70. Approximately 892,106 shares changed hands during trading, an increase of 556% from the average daily volume of 135,968 shares. The stock had previously closed at C$1.37.
Analyst Upgrades and Downgrades
Separately, Jones Trading lowered shares of Oncolytics Biotech from a "strong-buy" rating to a "hold" rating in a research note on Friday, May 16th.
Read Our Latest Report on Oncolytics Biotech
Oncolytics Biotech Trading Up 6.0%
The firm has a market capitalization of C$123.32 million, a price-to-earnings ratio of -4.46 and a beta of 1.35. The firm's 50 day moving average is C$0.82 and its 200 day moving average is C$0.94. The company has a quick ratio of 8.86, a current ratio of 2.99 and a debt-to-equity ratio of 11.75.
About Oncolytics Biotech
(
Get Free Report)
Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.
Further Reading
Before you consider Oncolytics Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oncolytics Biotech wasn't on the list.
While Oncolytics Biotech currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
